shelf(0)

No. 010 · GH & Growth · Growth Hormone

CJC-1295 No DAC

Mod GRF (1-29)Modified GRF 1-29Tetrasubstituted GRF(1-29)

C Tier C · Animal data how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
CJC-1295 No DAC (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER C — Evidence comes mostly from animal studies.

Published data are mostly preclinical; no completed human trials of this compound were found.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

A modified GRF (1-29) analog without the drug-affinity complex, providing a shorter-acting but more pulsatile GH release pattern that mimics natural physiology.

Research status Extensive clinical research as modified GRF; well-established pharmacokinetic profile

04

Mechanism

CJC-1295 no DAC (modified GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH release via adenylyl cyclase/cAMP signaling. Without the DAC moiety it has a half-life of approximately 30 minutes, producing a sharp GH pulse that closely mimics the natural pulsatile secretion pattern.

05

Effects reported in research

Reported outcomes, not promises. These come mostly from preclinical (cell or animal) research and have not been confirmed in human trials.

  • Pulsatile growth hormone release
  • Improved body composition
  • Better sleep architecture
  • Synergistic effects when paired with a GHRP
06

Safety & unknowns

Well-tolerated in clinical settings. Short half-life means lower risk of sustained IGF-1 elevation compared to DAC variant. Common side effects: flushing, headache, dizziness. Not FDA-approved.

Unknowns. No randomized controlled trials in humans have been published, so human safety has not been established in controlled studies.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [1]

  1. Clinical trial 2006

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism

    Key study on the CJC-1295 molecule platform demonstrating its GH-stimulatory properties in humans.

    [pubmed]

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). CJC-1295 No DAC. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/cjc-1295-no-dac/

$ cite --format=bibtex 
@misc{peptidemeta-cjc-1295-no-dac,
  title = {CJC-1295 No DAC},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/cjc-1295-no-dac/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open